Quantum Biopharma Ltd.
QNTM
Positions held
Your positionsQNTM isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $20.00M | Enterprise value | $20.40M | Trailing P/E | — | Forward P/E | -0.40 |
| PEG | — | Price / book | 2.96 | Beta | 0.38 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -6.2% | ROA | -51.8% | Debt / equity | 0.16 |
| Current ratio | 1.20 | Free cash flow | -$5.03M | Analyst recommendation | none | Mean target | $12.26 |
| 52w high | $16.36 | 52w low | $2.07 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$3.3M | -$13.6M | -$3.0M | -$5.3M | -$9.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$2.3M | -$2.9M | -$2.4M | -$4.7M | -$4.9M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$26.2M | -$14.2M | -$17.9M | -$23.6M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$15.3M | -$15.9M | -$19.6M | -$27.4M | — |
Headline risk — review
• [CRITICAL · legal] World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Can
News
2026-10-08 · Why Thermo Fisher Scientific (TMO) Is Back In The Spotlight
2026-10-07 · Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial
2026-10-06 · Quantum BioPharma (QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
2026-10-06 · Quantum BioPharma, Thermo Fisher Partner on Phase 2 Multiple Sclerosis Trial
2026-10-06 · EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
2026-09-25 · Quantum BioPharma (QNTM) Receives FDA Green Light to Move Lucid-MS Into Phase 2 Testing
2026-09-23 · Quantum BioPharma (QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
2026-09-17 · Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
Price (daily)
Full chart · RSI · MACD · patterns